Try our Advanced Search for more refined results
Life Sciences - February, 2019
342 articles
- Del. Chancellor Accused Of Not Disclosing Conflict While Atty
- CIT Gives Duty Break To McKesson's Drug Dispensers
- Relators Claim No Notice Of Dismissal In $70M FCA Suit
- Original FTC V. Actavis Case Ends With AbbVie AndroGel Deal
- DLA Piper Adds Partner To Miami Corporate Practice
- Fed. Circ. Clears Perrigo's Generic Pepcid In Patent Case
- Abbott Test Strip Fight Triggers Defense Duty: Wis. Justices
- Alaska Republican Floats Bill To Let Tribes Regulate Marijuana
- Keryx Says It Didn't Mislead Investors On Drug's Production
- Teva Can't Beat Whistleblowers' FCA Suit Over Paid Speakers
- UK Accuses Drugmakers Of Anti-Competitive Agreements
- CVS Falsely Told Docs Patients Wanted Scripts, Suit Says
- 3rd Circ. Limits Scope Of FTC Judicial Enforcement Authority
- Stryker Beats Ex-Sales Rep's Age Bias Suit Over Firing
- Genetics Co. Raises $191M In Venture Funding
- Risks Of Promoting Products As 'Safe' For Pregnant Women
- Kaleido Biosciences Prices $75M IPO Below Range
- Bristol-Myers Fights Investor Pushback On $74B Celgene Buy
- J&J Rep Pressed On Internal Tests In Talc Cancer Trial
- Monsanto MDL Judge Sanctions 'Steely' Atty, Explains Remark
- Teva Must Pay $500K In Legal Bills Over Ex-Exec's Firing
- Teva Can't Fight FDA's New Generic-Exclusivity Policy: Judge
- University Wants IP Back After Prof. Allegedly Stole Research
- Parts Of Skin Care Patents Likely Invalid But No PTAB Review
- Genentech Profits Off Wasteful Cancer Drug Vials, Suit Says
- 7th Circ. Says Imaging Co. Can't Nix $15M Cancer Suit Award
- Hikma Urges Justices To Eye Ruling On Medical Treatment IP
- Pomerantz To Rep Investors In Acadia Drug Deaths Case
- Gibson Dunn, Latham Steer Ultragenyx's $304M Follow-On
- Real Estate Rumors: Bridge, Albert Behler, Lightstone
- Novartis Ducks More Damages In Whistleblower Suit
- Sarepta Inks $165M Myonexus Buy In Gene Therapy Deal
- Merck Launches $6B Threat To Versum-Entegris Deal
- What To Expect From USPTO On Patent Term Post-Supernus
- Banks Should Prepare For Federal Marijuana Legalization
- Blackstone Forms New Biotech With Initial $250M Investment
- Deals Rumor Mill: ChemChina, Cerberus, Nexon
- Better Late Than Never? Not So For Class Cert. Appeals
- Monsanto MDL Judge Slams Female Atty's 'Steely' Composure
- Bayer Beats Certified Class In $600M Vitamin Labeling Row
- 3rd Circ. Kills Lotion TM Case Against Cetaphil Maker
- 9th Circ. Affirms Ex-Bio-Rad GC's $8M Whistleblower Win
- AbbVie Investors Want Records On Testosterone Marketing
- Lilly Gets PTAB To Review 6 Teva Migraine Biologic Patents
- Chemical Co. Sued For Allegedly Abusing Retirement Plans
- Big Pharma Largely Unscathed After Capitol Hill Showdown
- Tech, Life Science IPOs Set To Remain Strong In 2019
- Oyster Pharma Sees $93M Funding Round For Dry Eye Drugs
- NECC Execs Say Conspiracy Convictions 'Legally Impossible'
- Supreme Court Urged Once Again To Clarify Key FCA Dispute
- Bristol-Myers Ends Abilify MDL With Confidential Settlement
- Court 'Science Days' May Not Benefit All Parties Equally
- Novartis Hit With $1.5M Whistleblower Verdict In NJ
- Weeding Out Meritless Claims In Multidistrict Litigation
- Biz Groups Mobilize For NAFTA 2.0 As Trump Presses Dems
- Missed Appeal Deadline Can't Be Extended, Justices Rule
- Amgen's Cholesterol Drug Patents Are Valid, Jury Says
- 'Sugar Bear Hair' Maker Sues Over Knockoff Gummy Vitamins
- Senators Must Get To The Root Of High Drug Prices
- Don't Advance Drug Antitrust Claims, Express Scripts Urges
- Hogan Lovells Nabs Life Sciences IP Duo From Venable
- Vanda Hid Off-Label Fraud Scheme From Investors, Suit Says
- Pharmas Inflating Info Leak To Unseat Patent Loss, Rival Says
- Monsanto MDL Judge Threatens Atty Sanctions As Trial Starts
- City Bellwethers In Opioid MDL Carved Out, Delayed
- Calif. County Can't Get Deal Over Stroke Medication Tossed
- Amarin Hit With Stock Drop Suit Over Drug Trial Results
- Patent-Busting A Hard Sell For Public Health Activists
- German Dialysis Firm Fresenius Notches Deal In FCPA Probe
- FTC Can't Challenge Past Conduct In Court, 3rd Circ. Says
- Winning PTAB Args Should Be OK For Court, Fed. Circ. Hears
- Sinovac Uses Poison Pill To Weaken Dissident Shareholders
- Bayer Seeks Fees After $155M Hemophilia Drug IP Verdict
- Boehringer Must Show How IP 'Thicket' Blocked Humira Rival
- 'The Spiel' Helped Insys Get Opioid Spray Paid For, Exec Says
- Kirkland Steers Close Of $2.1B SK Capital Fund
- 4 Firms Guide Ipsen's $1.3B Clementia Pharma Deal
- Diplomat Pharmacy Misled Investors About New Venture: Suit
- Venture-Backed Medical Device Biz Launches $75M IPO
- Goodwin, Davis Polk Lead Roche's $4.8B Spark Buy
- Manufacturers Can Curb Influencers' Fanciful Product Claims
- 3 Firms Steer GE's $21B Sale Of Biopharma Unit To Danaher
- Consultants Aim To Send GSK Probe Suit Back To State Court
- Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet
- 3 Things To Watch At Monsanto's Roundup Bellwether Trial
- Generics Cos. Say No Grand Conspiracy In Price-Fixing MDL
- Drugmaker To Pay $4M To End Claims It Dodged FDA Fees
- Texas Pharma Sales Rep Pleads Guilty To $8M Fraud
- Deals Rumor Mill: Sika, Berkshire Hathaway, Centogene
- Synergy Pharma Faces Pushback Over Ch. 11 Plan Releases
- Neurotech Startup Closes $28M Round Led By Alphabet Unit
- Novartis, Express Scripts Beat Kickback Suit Over Discounts
- FDA Focus: What Sidley Austin's Practice Chair Is Watching
- Insys Rode 'The Gray Line' To Mislead Insurers, Exec Says
- Baylor Med School Denied Attys' Fees In Cancer IP Row
- US Scientists Belong On Cancer Patents, Judge Hears
- Greenspoon Marder Unit, Squire Patton Back Pot Roundtable
- WuXi Accused Of Shorting Investors In Go-Private Deal
- Amgen, Teva Cut Illegal Deal To Pull Generic, Suit Says
- Health Hires: DLA Piper, Baker McKenzie, Taft, Buchalter
- A Holistic Approach To Compliance For Cannabis Cos.
- 3 Lessons From A Crypto Mock Trial
- Arizona High Court Puts Stengel Claims In Doubt
- Tracing Puerto Rico's Journey Through Bankruptcy
- UK's SFO Drops Corruption Probes Into Rolls-Royce, GSK
- Jury Verdict Clearing Allergy Advocacy Group Stands: Judge
- Ex-Novartis Exec's Whistleblower Claim A Lie, NJ Jury Told
- J&J's Expert Tells Calif. Jury Talc Doesn't Cause Cancer
- Lipocine Hit By Investor With Testosterone Drug 'Scheme' Suit
- 2nd Circ. Saves FTC Oversight Of Red-Hot Memory Aid Sector
- Specialty Pharma Co.'s $34M Ch. 11 Financing OK'd
- Rare Disease Biotech Mereo BioPharma Pulls $70M US IPO
- Onyx's Patent Agent Privilege Claim Fails In Cancer Drug Row
- Canada Closes Antitrust Probe Into Janssen Over Biosimilars
- Ex-Biotech Exec Settles SEC Insider-Trading Case For $148K
- NY, Fla. Buyers Favored For Cert. In Gerber False Ad Suit
- Amgen Asks Fed. Circ. To Uphold $70M Hospira IP Verdict
- MPM Capital Closes Biotech-Focused Fund With $400M
- 2 Firms Steer Merck's $300M Immune Design Deal
- HHS Is Embracing A Broader Vision Of Health Care
- Explainability: Where AI And Liability Meet
- ResMed, Fisher & Paykel End Sleep Mask Patent Fight
- Squire Patton Boggs Snags Patent Prosecutor Todd Lorenz
- J&J Subpoenaed Over Claims Of Asbestos In Baby Powder
- FTC's Teva Settlement A Sign Of Enforcement Evolution
- 2nd Circ. Judge Must Exit FTC Case, Supplement Co. Says
- Fed. Circ. DQs Katten Over Conflicts In Mylan Patent Case
- Fresenius Asks Chancery For Fast Akorn Damages Ruling
- Amphastar Says Rivals' Patent Loss Is Antitrust Ammo
- OptumRx Owes Workers' Comp Fund $16M, Ohio AG Says
- Monsanto Gets Gift With Two-Stage Roundup Bellwether
- Calif. AG Pushes Bill Banning Generic Drug Pay-For-Delay
- Atty-Turned-Fraudster Loses 2nd Bid To Access SEC Files
- Judge Skeptical Of Ex-Novartis Exec's Whistleblower Claims
- Drug Co. Peloton Snags $150M In Funding For Cancer Trials
- A Chat With McDermott COO John Yoshimura
- Bristol-Myers Gives FTC More Time To Review $74B Merger
- Boston Scientific Says 50K Mesh Settlements Almost Final
- 2nd Recent FTC Split OKs Fresenius $2B Merger With Fixes
- DOJ Says Shuttered Abbott Unit Engaged In Kickback Scheme
- High Court Won't Block Dr. Reddy's Opioid Treatment
- Judge Limits Evidence For Roundup Bellwether Trial
- 'Absurd' To Argue PTAB Wins Bar Patent Cases: Generics Cos.
- Clyde & Co. Atty Describes Cancer's Shadow In J&J Talc Trial
- Opioid MDL Atty Gets Heat For Ripping Purdue 'Scumbags'
- Biotech Co. Says $3.6M Award Wrongly Calculated
- Chancery Awards Legal Costs In DAVA-Endo Merger Case
- Generics Cos. To Face Most State Claims In Price-Fixing MDL
- NJ Pain-Drug Maker Hits Ch. 11 With $75M Purchase Offer
- High Court Won't Hear Fight Over Md. Price-Gouging Law
- FTC Pens New Deal With Teva On Reverse-Payment Claims
- Mass. Biopharma Co. Launches IPO That Could Raise $120M
- Cochlear Targets US Rival In Patent Suit Over Hearing Implant
- Justices Reject Mylan's Challenge To 'Tactical' Drug Patenting
- The Problem With 'Optimal' Diversity
- The $1B Question: Can Puerto Rico Afford Its Bankruptcy Bills?
- Puerto Rico's Law Firms Find Their Footing After Disaster
- AbbVie, Eli Lilly Beat Insurer's RICO Suit in Testosterone MDL
- FTC Wants More Info On Boston Scientific's £3.3B BTG Buy
- Investor Reaffirms Suit Accusing Akorn Execs Of Deceit
- Ex-FDA Atty Joins McDermott Will & Emery's DC Office
- Ex-Vinson & Elkins Atty Joins Pillsbury In NY
- Trump's Drug Rebate Ban Faces Fraught Legal Path
- 'We're All Going To Jail,' Ex-Insys CEO Says He Heard At Work
- Restasis Patent Redo Bid 'Inappropriate,' Fed. Circ. Told
- Lamictal Case Won't Be Paused For Class Cert. Appeal
- Insulin Giants Beat RICO Claims Brought By Patients
- Gov't Opioid Suits Hide Attorneys' Personal Interests
- WilmerHale-Led Stealth Biotherapeutics Debuts With $78M IPO
- ITC Clears Japanese Dental Co. In Rival's Patent Suit
- A First Look At New HHS Prescription Drug Safe Harbors
- Coca-Cola-Tied Engineer Stole IP For Chinese Co., DOJ Says
- AbbVie Execs Hit By Another Suit Over Drug, Stock Schemes
- Mo. High Court Lets J&J Move Talc Trial To St. Louis County
- Retailer Shopko Seeks To Investigate McKesson In Ch. 11
- UPS Suit Delivers Warning To Cannabis Co.: Stop Using Marks
- Walgreens, Kroger Slam J&J's Challenge To Antitrust Claims
- Bankrupt Imerys Dropped From Dying Woman's J&J Talc Trial
- Insys Directors Say Criminal Trial Still Stops Chancery Case
- 2 VC-Backed Health Care Cos. Price IPOs Totaling $145M
- Nektar Hit With Derivative Suit Over Drug Trial Results
- Reps Challenge FDA On Foreign Drug Monitoring After Recalls
- Ex-Insys CEO Says Founder Called Him Company's 'Fall Guy'
- Subsys-Prescribing Doc Cops To Kickback Conspiracy
- Perrigo, Ex-Execs Left 'Financial Bloodbath,' $555M Suit Says
- Reasons To Limit Inventor Testimony In Hatch-Waxman Cases
- Gene-Editing Co. Cibus Delays IPO, Citing Market Conditions
- Investors Inject $125.5M Into Early Cancer Detection Co.
- DC Firm Helped Ranbaxy Avoid FDA Scrutiny, RICO Suit Says
- Brain Fingerprinting Tech Row Sent To Arbitration
- VIDEO: Insys Exec Dances As Bottle Of Fentanyl Spray
- Covington Snags Ex-Wilson Sonsini Tech M&A Pro In Calif.
- J&J Talc Supplier Seeks Ch. 11 Amid Asbestos Suit Tidal Wave
- Insys Thought It 'Owned' Doctors, Former CEO Testifies
- DOJ Flexes New Muscles In Opioid Fight
- Innovative And Ineligible: Diagnostic Patents At Fed. Circ.
- How Calif. Cannabis Rules Will Impact Investors And Lenders
- Lowered Bar For BIPA Lawsuits Will Raise Insurance Issues
- Cravath, Wachtell Advise On J&J's $3.4B Auris Health Deal
- Big Pharma Peers Won't Follow J&J On Price Transparency
- 3 Takeaways From The Latest Ax Of A Diagnostic Patent
- Proposed Opportunity Zone Regs Hazy On Marijuana Projects
- Fed. Circ. Says UK DNA Sequencers Don't Infringe IP In US
- Ex-Insys CEO Says Founder Demanded Aggressive Marketing
- Deals Rumor Mill: DoorDash, Rivian, BASF
- PTAB Won't Hear Dr. Reddy's Challenge To Revlimid Patents
- Tibet Pharma Observers Not Liable In IPO Row, 3rd Circ. Told
- VC-Backed Biopharma Co. Anchiano Launches $30.5M IPO
- Fresh Takes On Seeking Costs And Fees Under Rule 45
- Alere Dodges New Trial In Drug-Testing Patent Fight
- For Now, Competitive Generic Therapy Exclusivity Is A Mirage
- McKesson Rebuke For Rx Tampering Reaction A First For FDA
- Amphastar GC In On Docs Leak In Antitrust Suit, Cos. Say
- Roche To Settle Enzo Biotech IP Fight For $21M
- Texas Atty Can't Arbitrate Malpractice Suit, 1st Circ. Rules
- DOJ Backs Long FCA Filing Limit At Supreme Court
- SD Governor Looks To Stop Industrial Hemp Bill For Now
- Insys Paid For Painkiller Prescriptions, Nurse Tells Jury
- FDA Targets Alzheimer's Products In Supplement Crackdown
- J&J Can Avoid Mandatory-Arbitration Vote, SEC Says
- Monsanto Pegs Cancer On Obesity, Hep C In Roundup MDL
- $785M In Debt, Diagnostics Provider Files For Bankruptcy
- Spain's Competition Watchdog Targets Radiology Drug Makers
- NJ Medical Device Co.'s Ch. 11 OK'd In Delaware
- Collins Says Insider Trading Prosecutors Violated His Rights
- Fed. Circ. Backs J&J Trial Win In Contact Lens Patent Suit
- Retailers At Risk From New Glyphosate Liability Theories
- Judging A Book: Smith Camp Reviews 'Echo Of Its Time'
- ADEA Protections For Outside Applicants Still Up In The Air
- One Woman's Attempt To Rebuild After Hurricane Maria
- 'Now Is The Real Crisis': Puerto Ricans Struggle For Disaster Aid
- Looking To Start Over, Storm-Tossed Lawyers Land In Fla.
- AbbVie Must Detail Efforts To Kneecap Humira Biosimilars
- Top Cases And Developing Trends In FCA Litigation: Part 2
- DOJ Takes 'First Of Its Kind' Action Against Tenn. Pharmacies
- Cut $3.6M From Infringement Verdict, Supplement Co. Asks
- $62B Bayer-Monsanto Deal Gets Final OK Despite Pushback
- 11 Firms To Lead 6 IPOs Aiming To Price Before Feb. Pause
- Health Hires: Locke Lord, Sidley Austin, Butler Snow
- Drugmaker Avadel Gets Boost From Parent In Del. Ch. 11
- USPTO's Take On Reused PTAB Positions May Upend Strategy
- J&J Unit Dodges Suit Over Gastric Band Device Death
- 2nd Circ. Leans FTC's Way In Memory-Booster Battle
- Senate Judiciary Carves Out New IP Subcommittee
- Colgate Dodges Philly Talc Suit Just Before Trial Kickoff
- VC-Backed Gossamer Bio Begins Trading After $276M IPO
- Push To Legalize Cannabis Biz Deductions Made In Congress
- UK Litigation Roundup: Here's What You Missed In London
- The Role Of Data Analytics In Mass Torts
- Arnold & Porter Gets Product Liability Atty Back From FDA
- Top Cases And Developing Trends In FCA Litigation: Part 1
- 6 Of 7 J&J Talc Samples Contained Asbestos, Jury Told
- Bank Wants Out Of Drugmaker MannKind's Stock-Drop Suit
- Fed. Circ. Kills Patent Fight After Momenta Ditches Biosimilar
- Johnson & Johnson To Include Drug Cost Info In TV Ads
- Bitcoin Biz-Linked Pump-And-Dump Schemers To Pay $2.3M
- Zetia Pay-For-Delay MDL Should Press On, Magistrate Says
- Chancery Slashes Bylaw Suit Atty Fees To $50K From $300K
- Womble Bond Dickinson Opens Office In Houston
- Ill. Construction Unions Sue Pharma Cos. Over Opioid Crisis
- 'The Mooch' Talks Mayhem, Con Law, Lessons From Harvard
- Ex-Mass. State Worker Cops To Role In $12.7M Stock Fraud
- Now In Congress: State Of The Union, Border Wall, Syria
- Competition, Not Confiscation, Is Key To Lower Drug Prices
- CMS Price Transparency Push Trails State Initiatives
- Opioid MDL Judge Mulls BakerHostetler DQ, Vents Frustration
- Drugmaker Files Ch. 11, Blames Low-Selling Urination Drug
- J&J 'Captured' Regulators To Hide Talc Asbestos, Jury Told
- Sanitation Issues Spur FDA To Stop Drugmaking At Pharmacy
- Trump Health Care Outreach Gains Little Traction
- Deals Rumor Mill: EQT Partners, Cevian, Cboe Global
- Fed. Circ. Axes Athena Diagnostic Test Patent As Natural Law
- 4th Circ. Upholds PE Firm's $87M Heparin Suit Coverage Win
- Aralez Puts Forward Ch. 11 Plan Isolated From Toprol Sale
- Jefferies Uses New York Law To Escape Texas Investors' Suit
- Don't Force NAFTA Rewrite Vote, Key Dem Tells Trump
- WilmerHale-Led Stealth Biotherapeutics Aims For $81M IPO
- Why Proper Document Redaction May Be An Ethical Duty
- Full Fed. Circ. Won't Review $20M Cialis Marketing Verdict
- Cannabis Case Highlights New Patent Considerations
- State Of The Union Pushes For Drug Price Fixes
- Allergan Wants ITC To Eye Rival Version Of Botox
- Jury Says Takeda Unit Owes Bayer $155M Over Hemophilia IP
- Pharma Co. Seeks Justice Review Over Updating Statements
- Novum Pharma Taps Cash Collateral As It Seeks Ch. 11 Buyer
- It's Déjà Vu As Witness Aids Juror, Prompts Risperdal Mistrial
- Tough Sell On Cancer Link Awaits At 1st Philly Talc Trial
- FTC Permitted To Force Exec Testimony In AndroGel Trial
- Celgene Investor Says Info Scant On $74B Bristol-Myers Union
- GSK Can't Escape MDL Alleging Zofran Caused Birth Defects
- Fed. Circ. Revives Sanofi Bid To Amend Cancer Drug Patent
- Trading Firm Tries To Save $3.6M Int'l Arbitration Award
- Fed. Circ. Appears To Side With Eli Lilly Over Cancer Patent
- Ex-Teva Exec's $5M In Punitive Damages Is Chopped By Cap
- Ex-Akin Gump Atty Leaked Docs In Antitrust Suit, Co. Says
- Bernstein Litowitz To Helm Opko Health Pump-And-Dump Suit
- Puma Biotech Misled Investors About Cancer Trial, Jury Says
- Why I Became A Lawyer: A Refugee's Journey Of Firsts
- Experts Predict Strong 2019 For IPOs Amid Gov't Uncertainty
- GSK Extends Drug Pipeline Push With Up To €3.7B Merck Deal
- DC Boutique Nabs FDA Partner From Baker McKenzie
- 1st Circ. Ponders 'Possible' Meaning In Fidelity Market Case
- Farm Bill Gives Cannabis Companies Room To Grow
- Method-Of-Treatment Patent Eligibility: Step 1 And Done?
- Some Cannabis Restrictions In Fla. Could Soon Be Extinct
- Judge Warns Against Attys 'Feeding' Experts In Roundup MDL
- Drug Co. Reaches $17M Deal In False Claims Act Suit
- USPTO Says Successful PTAB Cases Can't Be Cloned In Court
- Bellwether Jury Awards $3M In Cook Medical Vein Filter MDL
- Delaware AG Can Pursue Fraud Claims Against Opioid Makers
- 11th Circ. Backs Sperm Bank's Win In Sham-Donor Suit
- Pfizer Should Face Label Suit, Robitussin Buyers Say
- McKesson Must Face Omni's FCA Suit Over Drug Skimming
- GSK Wants Chinese Consultants' Probe Claims Arbitrated
- Thermo Fisher's $4.7M Wage Deal Lacks Info, Judge Says
- Par Pharma Seeks To Void Merck Diabetes Drug Patent
- Deals Rumor Mill: Starboard, Smart & Final, Palo Alto
- NYT Article Was Defamation, OSU Scientist Tells 6th Circ.
- Recent Decisions Bode Well For False Claims Act Defendants
- Novum Pharma Opens $53M Del. Ch. 11 With Sale Plan
- 11th-Hour Deal Lets Pfizer Exit As Cancer Patent Trial Begins
- Thoratec Inks $11.9M Deal With Investors In Heart Device Suit
- 4 Tips For Medical Device Cybersecurity
- 3 Cos. Launch IPOs Totaling $250M Amid Early Feb. Rush
- Ex-Abiomed Exec Seeks To Revive $2.1M Wrongful Firing Suit
- Keeping PR Strategy Communications Privileged: Part 2
- A Hard Choice For Abbreviated Biologics License Applicants
- Ex-Pharma CEO Convicted Of $100M Puerto Rico Bank Fraud
- 7th Circ. Decision Overlooks Purpose Of Age Bias Law
- As Puerto Rico Recovers, Courts Heed Lessons Of Disaster
- Alere Settles Investor Claims Over Blood Monitor For $20M
- Calif. Judge Axes Suits Alleging Pradaxa Warnings Inadequate
- Purdue Brass 'Milked' $4B From Opioid Addiction: Mass. AG
- Drug Co. Founders Defend Legal Fees In $20M Chancery Suit
- 10 Firms Will Steer 6 IPOs Raising $724M To Start February
- AGs Want To Unlock Redacted Generic Price-Fixing Complaint
- Ex-Insys Exec Testifies On Blowing Up At Founder
- Target Customers Seek Cert. In B-Vitamin Class Action
- Ex-Stradling Yocca Partner Joins Loeb & Loeb's Tax Practice
- Fed. Circ. Says PTAB Right To Uphold Epilepsy Drug Patent
- Allergan Deal Gets Compounder To Say Drugs Not FDA-OK'd
- Keeping PR Strategy Communications Privileged: Part 1